Mycoses
Diseases caused by FUNGI.
Subtype terms (20)
More specific conditions that are subtypes of Mycoses in the MeSH hierarchy.
- Allergic Fungal Sinusitis
1 drug approved
- Aspergillosis
23 drugs (18 approved, 5 experimental)
- Candidiasis
49 drugs (30 approved, 19 experimental)
- Central Nervous System Fungal Infections
2 drugs approved
- Coccidioidomycosis
11 drugs (8 approved, 3 experimental)
- Cryptococcosis
6 drugs (5 approved, 1 experimental)
- Dermatomycoses
7 drugs (5 approved, 2 experimental)
- Eye Infections, Fungal
3 drugs (2 approved, 1 experimental)
- Geotrichosis
- Histoplasmosis
4 drugs approved
- Invasive Fungal Infections
24 drugs (17 approved, 7 experimental)
- Lung Diseases, Fungal
5 drugs (4 approved, 1 experimental)
- Microsporidiosis
1 drug experimental
- Otomycosis
9 drugs (4 approved, 5 experimental)
- Paracoccidioidomycosis
- Phaeohyphomycosis
- Piedra
- Pneumocystis Infections
8 drugs approved
- Trichosporonosis
- Zygomycosis
1 drug approved
Drugs by status
Approved for this indication (16)
Phase 4 trials (8)
Phase 3 trials (12)
Phase 2 trials (13)
Phase 1 trials (15)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (54)
- Ligand Pharmaceuticals
- Eisai
- Astellas
- Gilead Sciences
- Schering-Plough
- Merck
- Pfizer
- Mallinckrodt
- Xiamen Amoytop Biotech Co., Ltd.
- Yung Shin Pharm. Ind. Co., Ltd.
- Fundacion SEIMC-GESIDA
- PETHEMA Foundation
- National Center for Research Resources (NCRR)
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Pittsburgh
- Boston University
- Case Western Reserve University
- Cornell University
- European Group for Blood and Marrow Transplantation
- Katholieke Universiteit Leuven
- Johns Hopkins University
- Madrilenian Group of Cutaneous Lymphomas
- Mahidol University
- Mclean Hospital
- Melbourne Health
- Polish Lymphoma Research Group
- Radboud University
- Texas Tech University
- Universidad Autonoma de Madrid
- Universidad Complutense de Madrid
- +24 more
Organization Involved with Phase 3 Indications (54)
- Peninsula Pharmaceuticals
- Ache Laboratorios Farmaceuticos S.A.
- Seattle Genetics
- Basilea Pharmaceutica
- Millennium Pharmaceuticals
- Emergent BioSolutions
- Enzon
- Elorac, Inc.
- Laboratório Teuto Brasileiro S/A
- Proaparts srl
- Scynexis, Inc.
- Sponsor GmbH
- Center for International Blood and Marrow Transplant Research
- Medical Research Council
- National Cancer Institute (NCI)
- National Eye Institute (NEI)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Marrow Donor Program
- Medical University of Graz
- Cairo University
- University of London
- Dartmouth University
- Duke University
- University of Washington
- Meander Medical Center
- Medical College of Wisconsin
- Seoul National University
- University of Groningen
- Utrecht University
- Yonsei University
- +24 more
Organization Involved with Phase 2 Indications (79)
- 4SC AG
- Actelion
- Ceptaris
- Celgene
- Roche
- Genzyme
- AM-Pharma
- Amplyx Pharmaceuticals
- Angimmune LLC
- F2G Ltd.
- Innate Pharma
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Matinas Biopharma, Inc
- OncoSec Medical Incorporated
- miRagen Therapeutics, Inc.
- Affimed GmbH
- Neumedicines Inc.
- National Institutes of Health (NIH)
- University of Pennsylvania
- American Society of Clinical Oncology
- Cancer and Leukemia Group B (CALGB)
- Harvard University
- Emory University
- Temple University
- Grupo de Estudio de Infecciones en Transplantados
- Hoosier Cancer Research Network
- Institut Paoli-Calmettes
- Julius-Maximilians University
- James Graham Brown Cancer Center
- Latin American Cooperative Onco-Haematology Group - Peru
- +49 more
Organization Involved with Phase 1 Indications (27)
- Spectrum Pharmaceuticals
- Amgen
- Morphotek
- Eli Lilly
- Tibotec
- Arno Therapeutics
- GlaxoSmithKline
- Samyang Biopharmaceuticals Corporation
- Sorrento Therapeutics, Inc.
- Trillium Therapeutics Inc.
- Chong Kun Dang Pharmaceutical
- AIDS Malignancy Consortium
- Southwest Oncology Group
- University of Kansas
- Virginia Commonwealth University
- Wake Forest University
- Fudan University
- University of Cincinnati
- University of Cologne
- Boryung Pharmaceutical Company
- Pharmaceutical Research Associates, Inc. (PRA)
- University of North Carolina at Chapel Hill
- University of Wisconsin
- Shijiazhuang Pharma Group (CSPC)
- SciTech Development, LLC
- Inncelerex
- St. Jude Children's Hospital
Organization Involved with Other Experimental Indications (5)